A study of utility of Delta IGG as a prognostic marker in Guillain barre syndrome after IV immunoglobulin treatment

Background: Guillain-Barré syndrome (GBS) is an acute onset immune-mediated disease affecting  the  peripheral  nerve  also  its  root  Plasma exchange(PE) and intravenous immuno globulin(IVIG) have given evidence for faster recovery in GBS(4). IVIG treatment is comparatively costly but hospital stay duration is reduced. Other options include corticosteroids but have not shown benefit. Mortality of GBS is around 3%. Around 20 % patients have persisting neurological deficits and one half of these have severe disability. After a standard dose of IVIg treatment, GBS patients show a large variation in pharmacokinetics of IgG, which may be related to clinical outcome. The therapeutic dose of IVIg for GBS was empirically set at 2g per kg body weight, based mainly on the clinical experience in patients with immune deficiencies. Not all patients of GBS, however, show a good recovery after this standard dose. IVIg clearance may depend on disease severity and vary between individuals, implying that this dose may be suboptimal for some patients who might need DOSE adjustments for others the standard dose might be sufficient. Aims and Objectives: To study and determine the serum DELTA IgG values and evaluate its utility in the prognosis of Guillain Barre Syndrome after IVIG treatment.&nbsp